Áttétes emlőrák: vizsgálatok itt: Kína
37 of 224 trials · From ClinicalTrials.gov, checked 2026. november 18.. Ask the study team whether a trial fits you.
- No phaseTaking peopleA Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer
- Where
- Beijing, Changchun, Chengdu, Chongqing, Guangzhou, Guiyang, Haikou, Harbin, Hefei, Jinan, Lanzhou, Luoyang, Nanchang, Nanjing, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Taizhou, Weifang, Wenzhou, Wuhan, Xiamen, Xi'an, Yangzhou, Zhengzhou, Zhongshan
- Életkor
- 18 év and over
- People
- 500
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07347600 - No phaseTaking peopleA Real World Study of Sacituzumab Govitecan
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 100
- Run by
- Fudan University
See details and how to joinNCT06966141 - No phaseNot yet taking people in KínaAlbumin-Bound Paclitaxel (Ⅱ) in Patients With Advanced Breast Cancer
- Where
- Wuhan
- Életkor
- 18 év and over
- People
- 1372
- Run by
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT07899047 - No phaseTaking peopleMecapegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia in Advanced Breast Cancer
- Where
- Hangzhou
- Életkor
- 18 év and over
- People
- 200
- Run by
- Zheng Yabing
See details and how to joinNCT07899099 - No phaseNot yet taking people in KínaExploring Curative Model for Advanced Breast Cancer: a Single-center, Prospective Phase II Clinical Study
- Where
- Zhengzhou
- People
- 147
- Run by
- Henan Cancer Hospital
See details and how to joinNCT07888556 - No phaseTaking peopleA Real-World Observational Study of Intratumoral H101 Oncolytic Adenovirus Combined With Immune Checkpoint Inhibitors for Advanced Metastatic Breast Cancer
- Where
- Guangdong
- Életkor
- 18 év to 75 év
- People
- 15
- Run by
- Jie Yuan,MD
See details and how to joinNCT07850869 - No phaseTaking peopleTiming of ctDNA Testing in Advanced Breast Cancer
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 400
- Run by
- Geneplus-Beijing Co. Ltd.
See details and how to joinNCT07681323 - No phaseTaking peopleHER2-PET: Predicting T-DXd Efficacy and HER2 Heterogeneity
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 100
- Run by
- Fudan University
See details and how to joinNCT07586215 - No phaseTaking peopleA Real-world Study Observing Treatment Patterns and Clinical Results for Patients in China With Hormone Receptor-positive, HER2-negative Metastatic Breast Cancer.
- Where
- Nanjing
- Életkor
- 18 év and over
- People
- 2000
- Run by
- AstraZeneca
See details and how to joinNCT07743944 - No phaseNot yet taking people in KínaResearch on AI Models for Predicting Breast Cancer Treatment Effectiveness to Guide Her-2 Targeted ADC Therapy
- Where
- Hangzhou
- People
- 900
- Run by
- Zhejiang Cancer Hospital
See details and how to joinNCT07689929 - No phaseTaking peopleA Phase II Observational Clinical Study on the Relationship Between Cerebrospinal Fluid Drug Concentration and Efficacy of Trastuzumab Deruxtecan in Central Nervous System Metastatic Breast Cancer
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 60
- Run by
- Fudan University
See details and how to joinNCT07653893 - No phaseTaking peopleA Prospective, Multicenter, Observational Cohort Study to Evaluate the Efficacy and Safety of a Novel Anti-tumor Drug as a Radiosensitizer in Patients With Advanced Breast Cancer Brain Metastasis.
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 100
- Run by
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT06839547 - No phaseTaking peopleA Prospective, Multicenter, Observational Cohort Study Assessing the Efficacy and Safety of Radiotherapy-sensitized Immunotherapy in Advanced Breast Cancer
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 150
- Run by
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT06776861 - No phaseTaking peopleEfficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Different HER2 Expression Patterns
- Where
- Changde, Changsha, Dongguan, Foshan, Fuzhou, Guangzhou, Hangzhou, Hengyang, Hohhot, Nanjing, Shanghai, Shantou, Shaoguan, Shenzhen, Zhongshan, Zhuhai
- Életkor
- 18 év to 80 év
- People
- 800 worldwide
- Run by
- Sun Yat-sen University
See details and how to joinNCT06551220 - No phaseTaking peopleReal-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Breast Cancer
- Where
- Shanghai
- Életkor
- 18 év to 75 év
- People
- 300
- Run by
- Fudan University
See details and how to joinNCT07551050 - No phaseTaking peopleReal-World Treatment Pattern and Clinical Outcome With Influential Factors of HR+/HER2-aBC 1L Patients in China
- Where
- Bingjie
- Életkor
- 18 év to 99 év
- People
- 14 000
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07476170 - No phaseTaking peopleA Study on the Efficacy and Safety of Switching Between Two Targeted Strategies, HP+Chemotherapy and HPy+Chemotherapy, After Treatment Progression in HER-2 Positive Advanced or Metastatic Breast Cancer
- Where
- Zhejiang
- Életkor
- 18 év and over
- People
- 600
- Run by
- Zhejiang Cancer Hospital
See details and how to joinNCT07455188 - No phaseTaking peopleReal-world Studies of CDK4/6 Inhibitors
- Where
- Tianjin
- Életkor
- 18 év and over
- People
- 245
- Run by
- Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT07407439 - No phaseTaking peopleDalpiciclib in HR+/HER2- ABC
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 103
- Run by
- RenJi Hospital
See details and how to joinNCT06301438 - No phaseTaking peopleTo Investigate the Real-world Efficacy and Safety of Sacituzumab Govitecan for HER2 Negative Metastatic Breast Cancer Patients in China.
- Where
- Hangzhou
- Életkor
- 18 év to 75 év
- People
- 200
- Run by
- Zhejiang Cancer Hospital
See details and how to joinNCT06784921 - No phaseTaking peopleA Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
- Where
- Beijing, Chengdu, Dalian, Foshan, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Jiamusi, Kunming, Lianyungang, Luoyang, Nanchang, Nanjing, Nanning, Nantong, Ningbo, Qingdao, Shanghai, Shantou, Shenyang, Shenzhen, Taiyuan, Tangshan, Tianjin, Ürümqi, Weifang, Wenzhou, Xiamen, Xi'an, Xi’an, Xinxiang, Xuzhou, Yinchuan, Zengzhou, Zhengzhou, Zhongshan, Zhuhai
- Életkor
- 18 év and over
- People
- 800
- Run by
- Daiichi Sankyo
See details and how to joinNCT06210776 - No phaseTaking peopleTrastuzumab Deruxtecan in Advanced Breast Cancer
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 118
- Run by
- Wenjin Yin
See details and how to joinNCT07180264 - No phaseTaking peopleEfficacy and Safety of Dalpiciclib in Hormone Receptor-positive Advanced Breast Cancer
- Where
- Shijiazhuang
- Életkor
- 18 év and over
- People
- 420
- Run by
- Hebei Medical University Fourth Hospital
See details and how to joinNCT05578053 - No phaseTaking peopleRapid Assessment of Sentinel Lymph Node Metastasis Status Using a Pan-CK-targeting NIR-II Fluorescent Probe in Breast Cancer
- Where
- Kunming
- Életkor
- 18 év to 75 év
- People
- 60
- Run by
- Yunnan Cancer Hospital
See details and how to joinNCT07154563 - No phaseTaking peopleReal-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors, or T-DXd
- Where
- Changsha
- Életkor
- 18 év and over
- People
- 200
- Run by
- Hunan Cancer Hospital
See details and how to joinNCT07073755